MH
Matthew R Henn
See Remarks

Matthew R Henn insider trades: Seres Therapeutics (MCRB) stock sales

See Remarks, Seres Therapeutics Last trade May 18, 2026 25 Form 4 filings
$23K
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
13
Open-market trades
since 2020
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Matthew reports to the SEC

Open-market buys and sales

13 trades reported on SEC Form 4, newest first

DateStockTypeValue
May 18, 2026MCRB↓ Sell$580
Feb 15, 2026MCRB↓ Sell$754
Nov 15, 2025MCRB↓ Sell$22K
Aug 18, 2025MCRB↓ Sell$1K
May 16, 2025MCRB↓ Sell$561
Feb 18, 2025MCRB↓ Sell$3K
Nov 18, 2024MCRB↓ Sell$501
Oct 28, 2024MCRB↓ Sell$3K
Aug 16, 2024MCRB↓ Sell$775
May 15, 2024MCRB↓ Sell$838
Feb 16, 2024MCRB↓ Sell$5K
Oct 30, 2023MCRB↓ Sell$5K
Dec 1, 2020MCRB↓ Sell$2.5M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other MCRB insiders

Open-market trades in the last 12 months

About Matthew R Henn's insider trades

Matthew R Henn is See Remarks at Seres Therapeutics (MCRB). Since Dec 1, 2020, Matthew has reported no open-market purchases and 13 sales worth $2.5M on SEC Form 4. In the last 12 months: 3 sales ($23K).

Their filings also include option exercises (14 filings), grants and awards (13 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MCRB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.